Cargando…
Abstract 7 2023 Update: Development of COVID-19 Therapies from Birthing Tissues and Cord Blood
INTRODUCTION: The Coronavirus pandemic presents a fleeting opportunity to evaluate the safety and efficacy of advanced cell therapy products, such as Mesenchymal Stromal Cells (MSCs), against a virus that attacks multiple organs and causes respiratory distress. With the pandemic winding down, there...
Autores principales: | Verter, Frances, Couto, Pedro Silva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476961/ http://dx.doi.org/10.1093/stcltm/szad047.008 |
Ejemplares similares
-
2021 Update: Development of COVID‐19 Therapies from Birthing Tissues and Cord Blood
por: Verter, Frances, et al.
Publicado: (2021) -
Abstract 11 Outcome of Patients Treated with Umbilical Cord Blood and Homologous Serum Eye Drops
por: Buzzi, Marina, et al.
Publicado: (2022) -
Abstract 15 Safety of DUOC-01, Intrathecal Cord Blood-Derived Cellular Therapy, as an Adjunct to Allogeneic Cord Blood Transplantation in Children with Inherited Metabolic Diseases
por: Sun, Jessica, et al.
Publicado: (2022) -
Development of COVID‐19 Therapies from Birthing Tissues and Cord Blood
por: Verter, Frances, et al.
Publicado: (2020) -
Expanded Access Protocol of Umbilical Cord Blood Infusion for Children with Neurological Conditions: An Update
por: McLaughlin, Colleen, et al.
Publicado: (2021)